New registry tracks rezdiffra safety in pregnant NASH patients
Knowledge-focused
Recruiting now
This study is a registry that collects information on the safety of Rezdiffra (resmetirom) in women with NASH who took the drug during pregnancy or while breastfeeding, and their infants up to 12 months old. It does not give any treatment or change care—it simply observes and rec…
Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated May 01, 2026 16:00 UTC